Crossover comparison of benoxaprofen and naproxen in rheumatoid arthritis

J Rheumatol Suppl. 1980:6:109-15.

Abstract

This multicenter double-blind clinical trial compared the efficacy and safety of benoxaprofen and naproxen in the treatment of rheumatoid arthritis. The studies followed a crossover design which provided 6 wk therapy with each of the 2 study drugs. Benoxaprofen at a single daily dose of 600 mg compared favorably to naproxen, 750 mg, administered in 2 equally divided doses. All efficacy results indicated slightly more improvement with benoxaprofen although the difference between the 2 drugs was not significant. Side effects were generally mild and only 1 patient discontinued benoxaprofen therapy because of a reactivation of a duodenal ulcer.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Analysis of Variance
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / blood
  • Anti-Inflammatory Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Benzoxazoles / adverse effects
  • Benzoxazoles / blood
  • Benzoxazoles / therapeutic use*
  • Blood Sedimentation
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Naproxen / therapeutic use*
  • Patient Compliance
  • Propionates / adverse effects
  • Propionates / blood
  • Propionates / therapeutic use*
  • Time Factors

Substances

  • Anti-Inflammatory Agents
  • Benzoxazoles
  • Propionates
  • benoxaprofen
  • Naproxen